title: Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels.
abstract: The present study identified a novel salinomycin (Sal)-sensitization mechanism in cancer cells. We analyzed the signal proteins Akt, Jnk, p38, Jak, and Erk1/2 in cancer cell lines that had arrested growth following low amounts of Sal treatment. We also tested the signal molecules PI3K, PDK1, GSK3β, p70S6K, mTOR, and PTEN to analyze the PI3K/Akt/mTOR pathway. The results showed that Sal sensitization positively correlates with large reductions in p70S6K activation. Interestingly, Akt was the only signal protein to be significantly activated by Sal treatment. The Akt activation appeared to require the PI3K pathway as its activation was abolished by the PI3K inhibitors LY294002 and wortmannin. The Akt activation by Sal was conserved in the other cell lines analyzed, which originated from other organs. Both Akt activation and C-PARP production were proportionally increased with increased doses of Sal. In addition, the increased levels of pAkt were not reduced over the time course of the experiment. Co-treatment with Akt inhibitors sensitized the Sal-treated cancer cells. The results thereby suggest that Akt activation is increased in cells that survive Sal treatment and resist the cytotoxic effect of Sal. Taken together; these results indicate that Akt activation may promote the resistance of cancer cells to Sal.
authors: Research Institute, National Cancer Center, Ilsan-gu, Goyang-si, Gyeonggi-do 410-769, Korea. jua@ncc.re.kr
authors: Ju-Hwa
authors: JH
authors: Kim
authors: Ae-Ran
authors: AR
authors: Choi
authors: Yong Kee
authors: YK
authors: Kim
authors: Hyung Sik
authors: HS
authors: Kim
authors: Sungpil
authors: S
authors: Yoon
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002867:Chromones / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D009025:Morpholines / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D011714:Pyrans / Q000494:pharmacology*; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D000077191:Wortmannin; D000095662:Polyether Polyketides
chemical_list: D000730:Androstadienes; D002867:Chromones; D009025:Morpholines; D051057:Proto-Oncogene Proteins c-akt; D011714:Pyrans; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D000077191:Wortmannin; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C010327:salinomycin; D000095662:Polyether Polyketides
references: Biochem Biophys Res Commun. 2012 Feb 3;418(1):98-103
references: 22244892
references: Cancer Lett. 2007 Jun 18;251(1):1-16
references: 17125914
references: Ann Surg Oncol. 2011 Jun;18(6):1797-804
references: 21267784
references: Biochem Pharmacol. 2010 Feb 1;79(3):373-80
references: 19766599
references: Invest New Drugs. 2012 Aug;30(4):1311-8
references: 21573958
references: Biochem Biophys Res Commun. 2009 Dec 18;390(3):743-9
references: 19835841
references: Biochem Biophys Res Commun. 1975 Oct 27;66(4):1231-6
references: 1191289
references: Ann Med. 2006;38(3):200-11
references: 16720434
references: Curr Cancer Drug Targets. 2006 Nov;6(7):623-34
references: 17100568
references: Cell. 2009 Aug 21;138(4):645-659
references: 19682730
references: Biochem Biophys Res Commun. 2009 Sep 25;387(3):450-5
references: 19607816
references: Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7
references: 21788521
references: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6
references: 11717429
references: Blood Cells Mol Dis. 2010 Jun 15;45(1):86-92
references: 20444629
references: J Biol Chem. 2004 Mar 19;279(12):11051-64
references: 14704150
references: Cancer Lett. 2011 Dec 1;311(1):113-21
references: 21835542
references: Biochem Biophys Res Commun. 2010 Apr 16;394(4):1098-104
references: 20350531
references: Oncogene. 2003 May 22;22(21):3205-12
references: 12761490
references: Biochem Biophys Res Commun. 2006 Jun 16;344(4):1263-70
references: 16650817
references: PLoS One. 2010 Dec 14;5(12):e15288
references: 21179458
references: Int J Mol Sci. 2012 Oct 12;13(10):13169-82
references: 23202945
references: Br J Pharmacol. 2011 Feb;162(3):773-84
references: 20973777
references: Br J Cancer. 2012 Jan 3;106(1):99-106
references: 22215106
references: Oncogene. 2003 Apr 3;22(13):2034-44
references: 12673208
references: Oncogene. 2004 Apr 12;23(16):2934-49
references: 15077155
references: PLoS One. 2010 Dec 20;5(12):e15630
references: 21187973
references: Oncogene. 2000 Dec 27;19(56):6594-9
references: 11426644
references: Biochem Biophys Res Commun. 2012 Feb 24;418(4):616-21
references: 22301191
references: FEBS Lett. 2008 Jun 25;582(15):2319-24
references: 18538139
references: Cell Cycle. 2006 Apr;5(8):824-8
references: 16627995
references: J Antibiot (Tokyo). 1974 Nov;27(11):814-21
references: 4452657
references: Cancer Lett. 2011 Dec 27;313(2):137-44
references: 22030254
references: Gastroenterology. 2010 Sep;139(3):942-52
references: 20621681
references: J Antimicrob Chemother. 2006 Mar;57(3):489-97
references: 16415127